Quest Diagnostics (DGX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY24 Guidance

Quest Diagnostics (NYSE: DGX) reported Q4 EPS of $2.15, $0.04 better than the analyst estimate of $2.11. Revenue for the quarter came in at $2.29 billion versus the consensus estimate of $2.25 billion.

GUIDANCE:

Quest Diagnostics sees FY2024 EPS of $8.60-$8.90, versus the consensus of $8.99. Quest Diagnostics sees FY2024 revenue of $9.35-9.45 billion, versus the consensus of $9.39 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Quest Diagnostics (DGX) PT Raised to $245 at UBS
• MSC Industrial names Rob Kuhns as executive VP and CFO
• Labcorp acquires MLM Medical Labs to expand lab network